

Afirma Thyroid Cancer Classifier Tests

EviCore
By EVERNORTH

-
- This benefit/harm statement only applies to those jurisdictions that do not have Medicare guidance.
 - Based upon the guidelines and evidence provided in the clinical policy, following EviCore's criteria for Afirma Thyroid Cancer Classifier tests will ensure that testing will be available to those members most likely to benefit from the information provided by the assay. For those not meeting criteria, it ensures alternate management strategies are considered. However, it is possible that some members who would benefit from the testing, but do not meet clinical criteria, will not receive an immediate approval for testing.
 - 80% of patients with indeterminate thyroid nodules who undergo surgery without molecular testing are found to be Benign postoperatively
 - Afirma GSC combines RNA expression analysis of over 10,000 genes with advanced machine learning to provide:
 - a Benign result that can be trusted to conclusively rule out surgery
 - or a suspicious result with information on the presence/absence of molecular variant/fusions to confidently guide treatment